drugset / Trial / NCT04995159

Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System

NCT04995159

Not yet recruiting 2150 enrolled Lepu Medical Technology (Beijing) Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to verify the safety and efficacy of Lepu® NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System combined with different antiplatelet therapies in the treatment of coronary heart disease.

Timeline

Start
2021-09
Primary completion
2026-01
Completion
2028-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule
Subject Clopidogrel Small molecule
Background Ticagrelor Small molecule